​

YD Bio Stock (NASDAQ:YDES)

FinancialsChart
YD Bio by TradingView

Previous Close

$5.78

52W Range

$5.30 - $25.00

50D Avg

$8.40

200D Avg

$12.18

Market Cap

$441.46M

Avg Vol (3M)

$26.51K

Beta

0.22

Div Yield

-

YDES Company Profile

Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

TW

Employees

4

IPO Date

Aug 29, 2025

Website

YDES Performance

YDES Financial Summary

Dec 24Dec 23
Revenue$510.36K$350.13K
Operating Income$-1.46M$-9.85K
Net Income$-1.41M$13.56K
EBITDA$-1.28M$22.25K
Basic EPS--
Diluted EPS--

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
TBPHTheravance Biopharma, Inc.
VIRVir Biotechnology, Inc.
DAWNDay One Biopharmaceuticals, Inc.
GLUEMonte Rosa Therapeutics, Inc.
TYRATyra Biosciences, Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
GERNGeron Corporation
LENZLENZ Therapeutics, Inc.